scispace - formally typeset
D

Debbie C. Crans

Researcher at Colorado State University

Publications -  282
Citations -  12500

Debbie C. Crans is an academic researcher from Colorado State University. The author has contributed to research in topics: Vanadium & Vanadate. The author has an hindex of 59, co-authored 262 publications receiving 11050 citations. Previous affiliations of Debbie C. Crans include University at Buffalo & University of Texas at Tyler.

Papers
More filters
Journal ArticleDOI

Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?

TL;DR: The development of antineoplastic ruthenium therapeutic complexes NAMI-A, KP1019, and KP1339 entered clinical trials and DW1/2 is in preclinical levels, and the very robust, conformationally rigid organometallic Ru(II) compound DW1 /2 is a protein kinase inhibitor and presents new Ru( II) compound designs as anticancer agents.
Journal ArticleDOI

Chemistry and insulin-like properties of vanadium(IV) and vanadium(V) compounds.

TL;DR: Oral ammonium dipicolinatooxovanadium(V) is a clinically useful hypoglycemic agent in cats with naturally occurring diabetes mellitus and represents the first time that a well-characterized organic vanadium compound with the vanadium in oxidation state five has been found to be an orally effective hypogly diabetic agent in animals.
Journal ArticleDOI

Decavanadate (V10 O28 6-) and oxovanadates: oxometalates with many biological activities.

TL;DR: In vivo effects of decavanadate in piscine models demonstrated that antioxidant stress markers, lipid peroxidation and vanadium subcellular distribution is dependent upon whether or not the solutions administered contain decavan adate.
Journal ArticleDOI

Effect of vanadium(IV) compounds in the treatment of diabetes: in vivo and in vitro studies with vanadyl sulfate and bis(maltolato)oxovandium(IV).

TL;DR: VOSO(4) and VO(malto)(2) showed differences when levels of plasma glucose and blood V in diabetic rodents were compared, and in the formation of V-protein complexes with abundant serum proteins, which suggest that binding of V compounds to ligands in blood, such as proteins, may affect the available pool of V for biological effects.